RE:RE:RE:RE:RE:RE:Reason for Stock Price
RagingBull. I agree that most of the scientific analysis would also come to the "shareholders are retards" conclusion but there may be other factors. In my opinion I think the biggest impediment to moving the SP is the independent analyst idea that the company is only worth $1.50 Cdn/share in 12 months. Granted the market cap associated with this TP is less than 1 years projected US only revenue (barely 1 year reapplying discount rate) but that is the only target out there for the public to digest. Unbelieveably conservative for a biotech just granted a "Prioroty Review" though it may be, that is all we can expect. With the previously unforseen surging competition in the refractory market and the increased risk that comes along with a "Priority Review" you can't expect much more than 43 cents. So much uncertainty and confusion. Maybe we should be looking at some of these P2 companies if we really want a home run?